Carbohydrate analysis throughout the development of a protein therapeutic
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
This review discusses the challenges involved in the characterization of the glycosylation of therapeutic glycoproteins. The focus is on methods that are most commonly used in regulatory filings and lot release testing of therapeutic glycoproteins. The different types of assays for carbohydrate analysis are reviewed, including the distinction between assays appropriate for lot release or better suited to testing during early drug development or in-depth characterization of the glycosylation. Characteristics of the glycoprotein and production process that should be considered when determining the amount of testing, the number of different methods to employ and when the testing should be performed during development of protein therapeutics is also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Carbohydrate-Specific Receptors of the Liver
Ashwell, G., & Harford, J. (1982) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.51.070182.002531 · Cited by 1,914 · cited 1×
“Although the loss of in vivo activity in glycoprotein therapeutics is often attributed to the efficient clearance of undersialylated molecules by the hepatic asialo glycoprotein receptor [81], most often the role of carbohydrates in plasma clearance is more complicated than can be explained by the asialoglycoprotein r…”
BackgroundHuman uptake and incorporation of an immunogenic nonhuman dietary sialic acid
Tangvoranuntakul, P., Gagneux, P., Diaz, S., Bardor, M., Varki, N., Varki, A., & Muchmore, E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2131556100 · Cited by 625
Incorporation of a non-human glycan mediates human susceptibility to a bacterial toxin
Byres, E., Paton, A. W., Paton, J. C., Löfling, J. C., Smith, D. F., Wilce, M. C. J., Talbot, U. M., Chong, D. C., Yu, H., Huang, S., et al. (2008) · Nature · doi:10.1038/nature07428 · Cited by 233
Cited by
Fc glycans of therapeutic antibodies as critical quality attributes
Reusch, D., & Tejada, M. L. (2015) · Glycobiology · doi:10.1093/glycob/cwv065 · Cited by 404
Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins
Ghaderi, D., Taylor, R. E., Padler-Karavani, V., Diaz, S., & Varki, A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1651 · Cited by 372
“They must often be produced in mammalian expression systems because of the crucial influence of the location, number and structure of N-glycans on their yields, bioactivity, solubility, stability against proteolysis, immunogenicity and rate of clearance from the bloodstrea”
Ghaderi, D., Zhang, M., Hurtado-Ziola, N., & Varki, A. (2012) · Biotechnology and Genetic Engineering Reviews · doi:10.5661/bger-28-147 · Cited by 320
Glycan analysis of therapeutic glycoproteins
Zhang, L., Luo, S., & Zhang, B. (2016) · mAbs · doi:10.1080/19420862.2015.1117719 · Cited by 207
Human cells: new platform for recombinant therapeutic protein production
Swiech, K., Picanço-Castro, V., & Covas, D. T. (2012) · Protein Expression and Purification · doi:10.1016/j.pep.2012.04.023 · Cited by 178
Metadata
- Authors
- Higgins, E.
- Venue
- Glycoconjugate Journal
- Published
- 2009-11-04
- Volume
- 27
- Issue
- 2
- Pages
- 211-225
- ISSN
- 0282-0080 (ISSN-L)
- 1573-4986
- OpenAlex
- W2011540538
- Cited by
- 100
- References
- 3
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Carbohydrate analysis throughout the development of a protein therapeutic. https://app.cochat.ai/papers/10.1007/s10719-009-9261-x
- The paper
- Higgins, E. (2010). Carbohydrate analysis throughout the development of a protein therapeutic. Glycoconjugate Journal. https://doi.org/10.1007/s10719-009-9261-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.